AUTHORS
Stephen Douglas Smith, MD, Danielle Wallace, MD2, Jose C Villasboas, MD3, Antonio Pinto, MD4, Francesc Bosch, MD5, Carlos Grande Garcia, MD PhD6, Reid W Merryman, MD7, Norma Gutiérrez, MD, PhD8, Luca Arcaini9, Jean Pierre Marolleau, PhD10, Brian G Till, MD11, Cristina García Herce, MD12, Maria Rocio Figueroa Mora13, Sara Rattotti14, Pierre Morel Sr, MD/PHD15, Jean-Marie Carpier16, Philippe Rinaudo17, Jan Fagerberg, MD, PhD18, Pier Luigi Zinzani, MD, PhD19, Philippe Armand, MD20, Stephen Maxted Ansell, MD, PhD21
AFFILIATIONS
1 Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, United States
2 University of Rochester, Rochester, New York, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Fondazione 'G. Pascale', IRCCS, Naples, Italy
5 University Hospital Vall d’Hebron, Barcelona, Spain
6 Universidad de Navarra, Pamplona, Spain
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Hospital Universitario De Salamanca, IBSAL, Salamanca, Spain
9 Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
10 Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France, Amiens, France
11 Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, United States
12 University Hospital Vall d’Hebron, Barcelona, Spain
13 Universidad de Navarra, Pamplona, Spain
14 Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
15 Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France, Amiens, France
16 Enterome, Paris, France
17 Enterome, Paris, France
18 Enterome, Paris, France
19 University of Bologna, Bolgna, Italy
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background
EO was designed to expand pre-existing memory CD8 T cells that recognize non-self-proteins from gut bacteria and cross-react with BCAs. EO includes 4 HLA-A2 epitopes with molecular mimicry to CD20, CD22, CD37 and BAFF-receptor, and the CD4-epitope UCP2.
Methods
In trial EONHL1-20/SIDNEY (NCT04669171), EO was given subcutaneously with Montanide adjuvant to pts with HLA-A2 and R/R disease. Pts received ER2 = EO (300µg/peptide) q2 weekly (w) x4 then q4w x11 + L (20 mg/day, 21/28 days x12 cycles) + R (375 mg/m2, q1w x4 then q4w x4 cycles).
Immune responses were tested on peripheral blood mononuclear cells without in vitro expansion by EO-mimic/BCA peptide-specific tetramers/flow cytometry and expressed as sum % of CD8 T cells (among all peripheral CD8 T cells) specific for the 4 EO-mimic or 4 BCA peptides at a single timepoint (max response at any time).
Correlations between clinical efficacy and expansion of specific CD8 T cells were done in groups split at the median for max expansions (log-rank [LR]) and by groups with complete response (CR) vs no CR (investigator-assessed Lugano 2014 criteria; Mann-Whitney 2-sided tests [MW]).
Associations between 37 BLFs (related to patient, diagnosis, tumor burden, risk scoring systems, immune markers and prior treatments) and time-dependent efficacy outcomes (CR duration [DOCR], progression-free survival [PFS], time to next treatment [TTNT]) were analyzed by univariate analyses (LR) and for CR by Fisher’s exact 2-sided tests (FE). Associations between BLFs and expansion of specific CD8 T cells were analyzed by FE. Analyses were exploratory and hypothesis-generating; significance = p≤0.05 in BLFs with >3 pts/group considered; no adjustment for multiple testing.
Results
The 24 clinical efficacy evaluable pts had a median of 1 [range 1-4] prior therapy lines (L), with a median PFS on 1L of 28 months (mo; range 8-164 mo). Twenty pts were evaluable for immune analyses (4 not assayed yet). EO-mimic/BCA peptide specific CD8 T cells were detected in 80% (95% CI 56-94)/75% (95% CI 51-91) of pts; max median % (in positive pts) were 0.63% (range 0.04-5.28)/0.54% (range 0.10-3.21).
CR-rate with ER2 was 63% (95% CI 41-81) and median DOCR 35 mo (95% CI 14-NR). At a median follow-up 16.9 mo, the median PFS was 18.5 months (95% CI 4.0-NR), and median TTNT was 21.8 mo (95% CI 11.5-NR). Split FL (n=19)/MZL (n=5) CR-rates were 68%/ 40% (FE NS [no significant difference]), and DOCR/PFS/TTNT did not show any differences (LR NS).
Max expansion of BCA-specific CD8 T cells was higher for pts with CR vs pts without CR (MW p=0.007), and a higher max level of EO-expanded BCA-specific CD8 T cells were associated with a longer PFS (LR p=0.023) and a longer TTNT (LR p=0.009).
The only BLF possibly associated with <median expansion of EO-mimic/BCA peptide specific CD8 T cells was male gender (FE p=0.033).
ECOG 1 vs 0 and 3-4 vs 1-2 L of prior therapy were associated with lower CR-rates (FE p=0.047 for both). Lymphocyte-monocyte ratio (LMR)≤2 (LR p=0.002), refractoriness or PFS ≤24mo at last prior therapy (LR p=0.023-0.036) were associated with shorter DOCR.
Shorter TTNT and PFS were associated with immune markers (e.g. LMR≤2, low CD4/CD8/B cells) and prior treatment BLFs (e.g. prior 3-4 L or CAR-T, PFS 1L or last prior line ≤24mo, refractoriness to anti-CD20). Multivariable analysis evaluating CD8 T cell expansion alongside BLF’s for TTNT and PFS was not feasible due to small sample size and interrelationship between the multiple BLF’s.
Of note, POD24 (n=6 progression ≤24 mo on 1L chemoimmunotherapy; n=yes 6 vs no 18) did not indicate significantly worse CR/DOCR/PFS/TTNT/T cell expansion, nor did number of prior L of therapy (1 vs 2-4; n=16 vs 8) (all LR and FE test NS); CR-rate 50% both for patients with POD24 and 2-4 L of prior therapy.
Conclusions
Treatment with ER2 displayed a favorable safety profile (Hematological Oncology, 2025, 43, e92_70093) and achieved a CR-rate of 63% with a median DOCR of 35 mo in pts with R/R FL/MZL.
Supporting its mechanism, and indicating potential use as a predictive biomarker, EO induced specific CD8 T cells expansion was associated with CR, PFS and TTNT on ER2 therapy. Expansions occurred largely independently of baseline clinical and immune features.
EO warrants study in larger, homogenous cohorts of patients with FL and MZL, alone and in combination with other immunomodulatory therapies, to fully characterize its efficacy, relevant biomarkers, and optimal setting of use.
DISCLOSURES
Stephen Douglas Smith, MD: ADC Therapeutics, Astrazeneca, Beigene, Corvus Pharmaceuticals, Enterome, Genentech, Incyte Corporation, Kymera Therapeutics, Loxo Oncology, Pfizer Oncology, Viracta Therapeutics - Research Funding; Enterome - Research Funding; Natera - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); Beigene, Natera - Consultancy (Includes expert testimony)